NASDAQ:ARGXargenx Stock Price, Forecast & News

argenx's stock was trading at $133.81 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ARGX stock has increased by 70.9% and is now trading at $228.72. View which stocks have been most impacted by Coronavirus.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for argenx in the last year. There are currently 2 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for argenx.

argenx SE - (NASDAQ:ARGX) issued its quarterly earnings data on Thursday, May, 14th. The company reported ($1.87) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.72) by $0.15. The business earned $21.15 million during the quarter, compared to analysts' expectations of $18.08 million. View argenx's earnings history.

16 equities research analysts have issued 1 year price targets for argenx's shares. Their forecasts range from $125.00 to $258.00. On average, they expect argenx's share price to reach $220.40 in the next twelve months. This suggests that the stock has a possible downside of 3.6%. View analysts' price targets for argenx.

Press coverage about ARGX stock has been trending somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. argenx earned a daily sentiment score of 0.7 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about argenx.

Some companies that are related to argenx include Seattle Genetics (SGEN), Moderna (MRNA), NOVOZYMES A/S/S (NVZMY), BioNTech (BNTX), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Qiagen (QGEN), Repligen (RGEN), Adaptive Biotechnologies (ADPT), Acceleron Pharma (XLRN), Allogene Therapeutics (ALLO), Crispr Therapeutics (CRSP), Novavax (NVAX), Spark Therapeutics (ONCE) and China Biologic Products (CBPO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include GALAPAGOS NV/S (GLPG), AcelRx Pharmaceuticals (ACRX), Neurocrine Biosciences (NBIX), Crispr Therapeutics (CRSP), Netflix (NFLX), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), GW Pharmaceuticals PLC- (GWPH), DexCom (DXCM) and Exelixis (EXEL).

(ARGX) raised $65 million in an initial public offering on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

argenx trades on the NASDAQ under the ticker symbol "ARGX."

Shares of ARGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARGX stock can currently be purchased for approximately $228.72.

argenx has a market capitalization of $10.75 billion and generates $78.17 million in revenue each year. The company earns $-182,520,000.00 in net income (profit) each year or ($4.73) on an earnings per share basis. argenx employs 103 workers across the globe.

The official website for argenx is www.argenx.com.

argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The company can be reached via phone at 329-310-3400 or via email at [email protected]